Krka launches Tuloxxin - an affordable solution for Bovine Respiratory Disease (BRD) - Veterinary Practice
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now


Krka launches Tuloxxin – an affordable solution for Bovine Respiratory Disease (BRD)

Tuloxxin is based on a tried and trusted active and delivers efficacy with formulation and delivery method technology at exceptional value

Krka UK has introduced Tuloxxin, a new product for the treatment of Bovine Respiratory Disease (BRD) triggered by Mannheimia haemolytica, Histophilus somni, Pasterella multocida and Mycoplasma bovis. Based on proven active Tulathromycin, Tuloxxin offers additional benefits in terms of affordability and convenience in the treatment of BRD, one of the most significant diseases affecting cattle.

BRD is known to be challenging to treat for a range of reasons including its multi-factorial aetiology and identification of the cause. This can lead to delayed treatment and the cost of appropriate therapeutics. This, in turn, can increase the need for handling, causing stress to cattle, as well as potentially increasing the overall volume of antibiotics used.

Tuloxxin is based on the same formulation as the market leader; in cattle it is administered using a single subcutaneous injection; in sheep Tuloxxin is licensed for use in the treatment of foot rot associated with Dichelobacter nodosus and also in pigs for swine respiratory disease (SRD) administered via a single intra-muscular injection. Its fast-acting, one dose formulation supports compliance and so reduces stress to herds and flocks.

Commenting on the launch of Tuloxxin, Charlotte Read, Key Account Manager – Farm, at Krka, said: “Without rapid treatment, confirmed cases of BRD can cause significant problems for farmers, both in terms of herd productivity and welfare. In the short-term, it slows development and is a common cause of calf mortality. In the longer term it can also cause lasting lung damage, delays to first calving, and increased risk of culling.

“Whenever Krka launches a generic product, we aim to add some extra value to it. Tuloxxin is a good example. It is based on a tried and trusted active and delivers efficacy; with formulation and delivery method technology at exceptional value. We hope its launch will support vets in their appropriate choice of antibiotic for specific cases. In so doing, they will be protecting their clients’ cattle and profitability while also playing their part in reducing antimicrobial use.”

Tuloxxin is available now from all wholesalers.

Krka UK Ltd is the UK’s fastest growing animal health company (Kynetec Data September 2020) and is a subsidiary of Slovenia-based Krka, d. d. Novo Mesto. The company offers a range of high-quality generic pharmaceuticals and aims to offer its customers exceptional value, service and technical support.

Veterinary Practice

Improve Veterinary Practice (part of the Improve International Group) is an online knowledge and information hub for veterinary professionals across all specialties. It provides reliable, useful and interesting content, written by expert authors and covering small animal, large animal, exotics, equine and practice management
sectors of the veterinary surgeon and nursing professions.

Improve Veterinary Practice also offers a subscription-based membership, offering CPD courses and much more for the whole veterinary community.

Improve Veterinary Practice exists to inspire and inform your day-to-day work, and enable your ongoing professional development.

More from this author

Have you heard about our
IVP Membership?

A wide range of veterinary CPD and resources by leading veterinary professionals.

Stress-free CPD tracking and certification, you’ll wonder how you coped without it.

Discover more